Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Price to Earnings Ratio (P/E) on January 14, 2025: 43.50

Supriya Lifescience Limited Price to Earnings Ratio (P/E) is 43.50 on January 14, 2025, a 57.82% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Supriya Lifescience Limited 52-week high Price to Earnings Ratio (P/E) is 53.89 on November 22, 2024, which is 23.90% above the current Price to Earnings Ratio (P/E).
Supriya Lifescience Limited 52-week low Price to Earnings Ratio (P/E) is 22.61 on June 04, 2024, which is -48.01% below the current Price to Earnings Ratio (P/E).
Supriya Lifescience Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 33.97.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years